;PMID: 10443461
;source_file_2902.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..40] = [t:0..40]
;1)sentence:[e:46..122] = [t:46..122]
;2)section:[e:126..168] = [t:126..168]
;3)section:[e:172..292] = [t:172..292]
;4)sentence:[e:296..415] = [t:296..415]
;5)sentence:[e:416..519] = [t:416..519]
;6)sentence:[e:520..744] = [t:520..744]
;7)sentence:[e:745..882] = [t:745..882]
;8)sentence:[e:883..995] = [t:883..995]
;9)sentence:[e:997..1115] = [t:997..1115]
;10)sentence:[e:1116..1315] = [t:1116..1315]
;11)sentence:[e:1317..1392] = [t:1317..1392]
;12)section:[e:1396..1441] = [t:1396..1441]

;section 0 Span:0..40
;Biol Pharm Bull.  1999 Jul;22(7):679-82.
(SEC
  (FRAG (NNP:[0..4] Biol) (NNP:[5..10] Pharm) (NNP:[11..15] Bull) (.:[15..16] .)
        (CD:[18..22] 1999) (.:[23..29] Jul;22) (-LRB-:[29..30] -LRB-)
        (CD:[30..31] 7) (-RRB-:[31..32] -RRB-) (::[32..33] :) (CD:[33..35] 67)
        (CD:[35..36] 9) (HYPH:[36..37] -) (CD:[37..39] 82) (.:[39..40] .)))

;sentence 1 Span:46..122
;Trigonelline-induced neurite outgrowth in human neuroblastoma SK-N-SH cells.
;[94..107]:malignancy-type:"neuroblastoma"
(SENT
  (NP-HLN
    (NP
      (ADJP (NN:[46..58] Trigonelline) (HYPH:[58..59] -) (VBN:[59..66] induced))
      (NN:[67..74] neurite) (NN:[75..84] outgrowth))
    (PP-LOC (IN:[85..87] in)
      (NP (JJ:[88..93] human) (NN:[94..107] neuroblastoma)
          (NN:[108..115] SK-N-SH) (NNS:[116..121] cells)))
    (.:[121..122] .)))

;section 2 Span:126..168
;Tohda C, Nakamura N, Komatsu K, Hattori M.
(SEC
  (FRAG (NNP:[126..131] Tohda) (NNP:[132..133] C) (,:[133..134] ,)
        (NNP:[135..143] Nakamura) (NNP:[144..145] N) (,:[145..146] ,)
        (NNP:[147..154] Komatsu) (NNP:[155..157] K,) (NNP:[158..165] Hattori)
        (NNP:[166..168] M.)))

;section 3 Span:172..292
;Research Center for Ethnomedicines, Institute of Natural Medicine, Toyama 
;Medical and Pharmaceutical University, Japan.
(SEC
  (FRAG (NNP:[172..180] Research) (NNP:[181..187] Center) (IN:[188..191] for)
        (NNP:[192..206] Ethnomedicines) (,:[206..207] ,)
        (NNP:[208..217] Institute) (IN:[218..220] of) (NNP:[221..228] Natural)
        (NNP:[229..237] Medicine) (,:[237..238] ,) (NNP:[239..245] Toyama)
        (NNP:[247..254] Medical) (CC:[255..258] and)
        (NNP:[259..273] Pharmaceutical) (NNP:[274..284] University)
        (,:[284..285] ,) (NNP:[286..291] Japan) (.:[291..292] .)))

;sentence 4 Span:296..415
;Extension of dendrites and axons in neurons may compensate and rescue damaged
; neuronal networks in the dementia brain.
(SENT
  (S
    (NP-SBJ
      (NP (NN:[296..305] Extension))
      (PP (IN:[306..308] of)
        (NP
          (NP (NNS:[309..318] dendrites))
          (CC:[319..322] and)
          (NP (NNS:[323..328] axons))))
      (PP-LOC (IN:[329..331] in)
        (NP (NNS:[332..339] neurons))))
    (VP (MD:[340..343] may)
      (VP (VB:[344..354] compensate) (CC:[355..358] and) (VB:[359..365] rescue)
        (NP (VBN:[366..373] damaged) (JJ:[375..383] neuronal)
            (NNS:[384..392] networks))
        (PP (IN:[393..395] in)
          (NP (DT:[396..399] the) (NN:[400..408] dementia) (NN:[409..414] brain)))))
    (.:[414..415] .)))

;sentence 5 Span:416..519
;Our aim is to isolate and identify  constituents of coffee beans exhibiting
;neurite outgrowth activity.
(SENT
  (S
    (NP-SBJ (PRP$:[416..419] Our) (NN:[420..423] aim))
    (VP (VBZ:[424..426] is)
      (S-PRD
        (NP-SBJ (-NONE-:[426..426] *))
        (VP (TO:[427..429] to)
          (VP (VB:[430..437] isolate) (CC:[438..441] and)
              (VB:[442..450] identify)
            (NP
              (NP (NNS:[452..464] constituents))
              (PP (IN:[465..467] of)
                (NP
                  (NP (NN:[468..474] coffee) (NNS:[475..480] beans))
                  (VP (VBG:[481..491] exhibiting)
                    (NP (NN:[492..499] neurite) (NN:[500..509] outgrowth)
                        (NN:[510..518] activity))))))))))
    (.:[518..519] .)))

;sentence 6 Span:520..744
;Among the  extracts of raw and roasted coffee beans, a methanol fraction of
;the ethanol  extract (1 microg/ml) of raw beans increased significantly the
;percentage of  cells with neurites in human neuroblastoma SK-N-SH cells.
;[716..729]:malignancy-type:"neuroblastoma"
(SENT
  (S
    (PP (IN:[520..525] Among)
      (NP
        (NP (DT:[526..529] the) (NNS:[531..539] extracts))
        (PP (IN:[540..542] of)
          (NP
            (NP (JJ:[543..546] raw)
              (NML-1 (-NONE-:[546..546] *P*)))
            (CC:[547..550] and)
            (NP (VBN:[551..558] roasted)
              (NML-1 (NN:[559..565] coffee) (NNS:[566..571] beans)))))))
    (,:[571..572] ,)
    (NP-SBJ
      (NP (DT:[573..574] a) (NN:[575..583] methanol) (NN:[584..592] fraction))
      (PP (IN:[593..595] of)
        (NP
          (NP (DT:[596..599] the) (NN:[600..607] ethanol)
              (NN:[609..616] extract))
          (PRN (-LRB-:[617..618] -LRB-)
            (NP
              (NP (CD:[618..619] 1) (NN:[620..626] microg))
              (PP (SYM:[626..627] /)
                (NP (NN:[627..629] ml))))
            (-RRB-:[629..630] -RRB-))
          (PP (IN:[631..633] of)
            (NP (JJ:[634..637] raw) (NNS:[638..643] beans))))))
    (VP (VBD:[644..653] increased)
      (ADVP (RB:[654..667] significantly))
      (NP
        (NP (DT:[668..671] the) (NN:[672..682] percentage))
        (PP (IN:[683..685] of)
          (NP
            (NP (NNS:[687..692] cells))
            (PP (IN:[693..697] with)
              (NP (NNS:[698..706] neurites))))))
      (PP-LOC (IN:[707..709] in)
        (NP (JJ:[710..715] human) (NN:[716..729] neuroblastoma)
            (NN:[730..737] SK-N-SH) (NNS:[738..743] cells))))
    (.:[743..744] .)))

;sentence 7 Span:745..882
;Among subfractions of  this methanol fraction was a basic fraction (5
;microg/ml) which exhibited  significant neurite outgrowth activity.
(SENT
  (SINV
    (PP-PRD-TPC-2 (IN:[745..750] Among)
      (NP
        (NP (NNS:[751..763] subfractions))
        (PP (IN:[764..766] of)
          (NP (DT:[768..772] this) (NN:[773..781] methanol)
              (NN:[782..790] fraction)))))
    (VP (VBD:[791..794] was)
      (PP-PRD-2 (-NONE-:[794..794] *T*)))
    (NP-SBJ
      (NP (DT:[795..796] a) (JJ:[797..802] basic) (NN:[803..811] fraction)
        (PRN (-LRB-:[812..813] -LRB-)
          (NP
            (NP (CD:[813..814] 5) (NN:[815..821] microg))
            (PP (SYM:[821..822] /)
              (NP (NN:[822..824] ml))))
          (-RRB-:[824..825] -RRB-)))
      (SBAR
        (WHNP-1 (WDT:[826..831] which))
        (S
          (NP-SBJ-1 (-NONE-:[831..831] *T*))
          (VP (VBD:[832..841] exhibited)
            (NP (JJ:[843..854] significant) (NN:[855..862] neurite)
                (NN:[863..872] outgrowth) (NN:[873..881] activity))))))
    (.:[881..882] .)))

;sentence 8 Span:883..995
;Finally, trigonelline in the basic  fraction was identified to be active as
;far neurite extension was concerned.
(SENT
  (S
    (ADVP (RB:[883..890] Finally))
    (,:[890..891] ,)
    (NP-SBJ-1
      (NP (NN:[892..904] trigonelline))
      (PP (IN:[905..907] in)
        (NP (DT:[908..911] the) (JJ:[912..917] basic) (NN:[919..927] fraction))))
    (VP (VBD:[928..931] was)
      (VP (VBN:[932..942] identified)
        (S
          (NP-SBJ-1 (-NONE-:[942..942] *))
          (VP (TO:[943..945] to)
            (VP (VB:[946..948] be)
              (ADJP-PRD (JJ:[949..955] active))
              (ADVP (RB:[956..958] as) (RB:[959..962] far)
                (S
                  (NP-SBJ-2 (NN:[963..970] neurite) (NN:[971..980] extension))
                  (VP (VBD:[981..984] was)
                    (VP (VBN:[985..994] concerned)
                      (NP-2 (-NONE-:[994..994] *)))))))))))
    (.:[994..995] .)))

;sentence 9 Span:997..1115
;Treatment with trigonelline (30 microM) increased the percentage of cells
;with  neurites at 3 and 6 d after treatment.
(SENT
  (S
    (NP-SBJ
      (NP (NN:[997..1006] Treatment))
      (PP (IN:[1007..1011] with)
        (NP (NN:[1012..1024] trigonelline)))
      (PRN (-LRB-:[1025..1026] -LRB-)
        (NP (CD:[1026..1028] 30) (NN:[1029..1035] microM))
        (-RRB-:[1035..1036] -RRB-)))
    (VP (VBD:[1037..1046] increased)
      (NP
        (NP (DT:[1047..1050] the) (NN:[1051..1061] percentage))
        (PP (IN:[1062..1064] of)
          (NP
            (NP (NNS:[1065..1070] cells))
            (PP (IN:[1071..1075] with)
              (NP (NNS:[1077..1085] neurites)))))
        (PP-TMP (IN:[1086..1088] at)
          (NP
            (NP
              (NP (CD:[1089..1090] 3)
                (NML-1 (-NONE-:[1090..1090] *P*)))
              (CC:[1091..1094] and)
              (NP (CD:[1095..1096] 6)
                (NML-1 (NN:[1097..1098] d))))
            (PP (IN:[1099..1104] after)
              (NP (NN:[1105..1114] treatment)))))))
    (.:[1114..1115] .)))

;sentence 10 Span:1116..1315
;In addition, the number of neurites  reacting positively to phosphorylated
;neurofilament-H was increased by treatment  with 30 microM trigonelline for 6
;d, suggesting enhancement of axonal extension.
(SENT
  (S
    (PP (IN:[1116..1118] In)
      (NP (NN:[1119..1127] addition)))
    (,:[1127..1128] ,)
    (NP-SBJ-1
      (NP (DT:[1129..1132] the) (NN:[1133..1139] number))
      (PP (IN:[1140..1142] of)
        (NP
          (NP (NNS:[1143..1151] neurites))
          (VP (VBG:[1153..1161] reacting)
            (ADVP (RB:[1162..1172] positively))
            (PP-CLR (TO:[1173..1175] to)
              (NP (VBN:[1176..1190] phosphorylated)
                  (NN:[1191..1206] neurofilament-H)))))))
    (VP (VBD:[1207..1210] was)
      (VP (VBN:[1211..1220] increased)
        (NP-1 (-NONE-:[1220..1220] *))
        (PP (IN:[1221..1223] by)
          (NP-LGS
            (NP (NN:[1224..1233] treatment))
            (PP (IN:[1235..1239] with)
              (NP
                (NP
                  (NML (CD:[1240..1242] 30) (NN:[1243..1249] microM))
                  (NN:[1250..1262] trigonelline))
                (PP (IN:[1263..1266] for)
                  (NP (CD:[1267..1268] 6) (NN:[1269..1270] d)))))))
        (,:[1270..1271] ,)
        (S-ADV
          (NP-SBJ (-NONE-:[1271..1271] *))
          (VP (VBG:[1272..1282] suggesting)
            (NP
              (NP (NN:[1283..1294] enhancement))
              (PP (IN:[1295..1297] of)
                (NP (JJ:[1298..1304] axonal) (NN:[1305..1314] extension))))))))
    (.:[1314..1315] .)))

;sentence 11 Span:1317..1392
;These results show that trigonelline promotes functional neurite outgrowth.
(SENT
  (S
    (NP-SBJ (DT:[1317..1322] These) (NNS:[1323..1330] results))
    (VP (VBP:[1331..1335] show)
      (SBAR (IN:[1336..1340] that)
        (S
          (NP-SBJ (NN:[1341..1353] trigonelline))
          (VP (VBZ:[1354..1362] promotes)
            (NP (JJ:[1363..1373] functional) (NN:[1374..1381] neurite)
                (NN:[1382..1391] outgrowth))))))
    (.:[1391..1392] .)))

;section 12 Span:1396..1441
;PMID: 10443461 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1396..1400] PMID) (::[1400..1401] :) (CD:[1402..1410] 10443461)
        (NN:[1411..1412] -LSB-) (NNP:[1412..1418] PubMed) (::[1419..1420] -)
        (NN:[1421..1428] indexed) (IN:[1429..1432] for)
        (NNP:[1433..1441] MEDLINE-RSB-)))
